YH009 is an innovative monoclonal antibody that we are developing for the prevention and treatment of RSV infection. YH009 demonstrates a strong neutralization effect on RSV and a good binding affinity with the F protein of different RSV subtype strains. YH009 is currently at CMC stage.
